Gentherm Reports 2019 First Quarter Results

Apr 30, 2019

Company Achieved Organic Automotive Revenue Growth Despite Industry Headwinds 
Secured $400 Million in Automotive Awards 
Maintains Full-Year 2019 Guidance and 2021 Outlook

NORTHVILLE, Mich., April 30, 2019 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader and developer of innovative thermal management technologies, today announced its financial results for the first quarter ending March 31, 2019.

First Quarter Highlights

  • Product revenues of $257.9 million decreased 2.5% from $264.6 million in the 2018 first quarter. Excluding the impact of foreign currency translation, product revenues were flat year over year
  • Excluding the impact of foreign currency translation, divested assets and assets held for sale, product revenues increased 3.0% year over year
  • GAAP diluted earnings per share was $0.25 as compared with $0.35 for the prior-year period
  • Adjusted diluted earnings per share (see table herein), was $0.55. Adjusted diluted earnings per share in the prior-year period was $0.52
  • Secured automotive new business awards totaling $400 million in the quarter

Phil Eyler, the Company's President and CEO, said “I am pleased with the continued progress we are making with our focused growth strategy, validated by our improving operating performance, innovative technology advances and our first Automotive News PACE award. Despite the production headwinds in the industry, we achieved organic revenue growth in automotive, significantly outperforming our key markets. We delivered year-over-year revenue growth in Climate Control Seat (“CCS®”) for the third consecutive quarter and secured $400 million of new awards from top auto makers around the world. In Medical, we delivered double-digit revenue growth both sequentially and year over year. In addition, we continue to improve our cost performance through the Fit-for-Growth program.”

2019 First Quarter Financial Review

Product revenues for the first quarter of 2019 decreased $6.7 million, or 2.5%, as compared with the prior-year period, essentially due to a $6.6 million decrease in the Industrial segment. Excluding the impact of divested assets and assets held for sale, product revenues increased $0.8 million, or 0.3%, year over year. Excluding the impact of foreign currency translation, divested assets and assets held for sale, product revenues increased 3.0% year over year.

Automotive revenues were flat due to higher sales in Climate Control Seat (“CCS®”) and Battery Thermal Management (BTM), offset by lower sales of seat heaters, steering wheel heaters and automotive cables. Adjusting for foreign currency translation, organic Automotive revenues increased 2.8% year over year.

Organic Automotive revenues grew despite lower than expected automotive production. When compared with IHS Markit's mid-February forecast for the first quarter of 2019, actual light vehicle production was approximately 2 percentage points below forecast. In addition, when compared to the first quarter of 2018, actual light vehicle production declined by approximately 6.7% in the Company’s key markets.

The revenue decline in Industrial resulted primarily from lower revenues from the Cincinnati Sub-Zero (“CSZ”) industrial chambers business, which was sold on February 1, 2019 and Global Power Technologies (“GPT”), which was classified as assets held for sale in the quarter. The decline was partially offset by a 12.3% growth in the medical business year over year.

See the “Revenues by Product Category” table enclosed herein for additional detail.

Gross margin rate declined to 29.2% in the current-year period, as compared with 30.7% in the prior-year period, primarily as a result of higher labor costs and the timing differences between annual customer price decreases compared to supplier cost reductions. These were partially offset by higher volume leverage and Fit-for-Growth cost reduction initiatives.

Net research and development expenses of $18.9 million in the 2019 first quarter decreased $4.4 million, or 18.9%. R&D expenses declined year over year, as a direct result of the Company’s focused portfolio and Fit-for-Growth cost reduction initiatives. Additionally, R&D expenses declined year over year due to higher customer reimbursements.  

Selling, general and administrative expenses of $32.6 million in the 2019 first quarter decreased $3.8 million, or 10.5%, versus the prior-year period. The year-over-year decline was primarily driven by the impact of the Fit-for-Growth cost reduction initiatives and the sale of CSZ industrial chambers business in the quarter.  

During the quarter, the Company recognized $1.9 million in restructuring expenses which resulted from completed actions associated with its Fit-for-Growth initiatives. Total implemented actions to date are expected to deliver annualized savings of approximately $41 million. The Company has identified a total of $65 million of savings against its annualized target of $75 million by 2021.

As described more fully in the table included below, “Reconciliation of Net Income to Adjusted EBITDA,” the Company recorded Adjusted EBITDA of $35.2 million in the 2019 first quarter compared with $34.5 million in the prior-year period, an increase of $0.7 million or 2.0%.

Income tax expense in the 2019 first quarter was $6.9 million, as compared with $3.0 million in the prior-year period. Adjusting for the $10.5 million non-deductible impairment loss, the effective tax rate for the quarter was 26.7%. This rate differed from the Federal statutory rate of 21%, primarily due to higher tax rates in foreign tax jurisdictions.

GAAP diluted earnings per share for the first quarter of 2019 was $0.25 compared with $0.35 for the prior-year period. Adjusted diluted earnings per share, excluding restructuring expenses, unrealized currency gain, and expenses and other impacts related to acquisitions (see table herein), was $0.55. Adjusted diluted earnings per share in the prior-year period was $0.52.

Guidance

The Company maintains its full-year 2019 guidance, excluding divested assets and assets held for sale, that was initially provided on its year-end 2018 earnings call on February 21, 2019:

  • Product revenues are expected to grow between 4% and 6% to a range of $1.01 billion to $1.04 billion
  • Operating expenses between 19% and 20% of product revenues
  • Gross margin rate between 28% and 30%
  • Adjusted EBITDA between 14% and 15% of product revenue
  • Full-year effective tax rate between 28% and 30%
  • Capital expenditures between $40 and $50 million

The Company also maintains the following outlook for 2021:

  • Product revenue growth of high single-digit CAGR for the 2018 to 2021 period
  • Operating expenses between 15% and 17% of product revenues
  • Gross margin rate between 30% and 32%
  • Adjusted EBITDA margin of high teens
  • ROIC of greater than 20%

Conference Call

As previously announced, Gentherm will conduct a conference call today at 8:00 am Eastern Time to review these results. The dial-in number for the call is 1-877-407-4018 (callers in the U.S.) or +1-201-689-8471 (callers outside this U.S.). The passcode for the live call is 13689375.

A live webcast and one-year archived replay of the call can be accessed on the Events page of the Investor section of Gentherm's website at www.gentherm.com.

A telephonic replay will be available at approximately 2 hours after the call until 11:59 pm Eastern Time on May 14, 2019. The replay can be accessed by dialing 1-844-512-2921 (callers in the U.S.), or +1-412-317-6671 (callers outside the U.S.). The passcode for the replay is 13689375.

Investor Relations Contact
Yijing Brentano
investors@gentherm.com
(248) 308-1702

Media Contact
Melissa Fischer
media@gentherm.com
248.289.9702

About Gentherm

Gentherm (NASDAQ:THRM) is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery thermal management systems, cable systems and other electronic devices. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has over 13,000 employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, Korea, Macedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam. For more information, go to www.gentherm.com.

Except for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this release are made as of the date hereof or as of the date specified and are based on management's current expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause the Company's actual performance to differ materially from that described in or indicated by the forward-looking statements. Those risks include, but are not limited to, risks that new products may not be feasible, sales may not increase, additional financing requirements may not be available, new competitors may arise or customers may develop their own products to replace the Company’s products, currency exchange rates may change unfavorably, pricing pressures from customers may increase, the Company’s workforce and operations could be disrupted by civil or political unrest in the countries in which the Company operates, free trade agreements may be altered in a manner adverse to the Company, cost-savings measures may not be achievable or may need to be reversed, assets held for sale may not be sold quickly or at all, the Company may be unable to repurchase its shares of common stock at favorable prices or at all, due to market conditions, applicable legal requirements, debt covenants or other restrictions, compliance with covenants and other restrictions under the Company’s credit facility, medical device regulations could change in an unfavorable manner, oil and gas prices could fluctuate causing adverse consequences, and other adverse conditions in the industries in which the Company operates may negatively affect its results. In addition, such forward-looking statements do not include the potential impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof.

The foregoing risks should be read in conjunction with other cautionary statements included herein, as well as in the Company's annual report on Form 10-K for the year ended December 31, 2018 and subsequent reports filed with the Securities and Exchange Commission. Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

GENTHERM INCORPORATED
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data) 
(Unaudited)
 
    Three Months Ended
March 31,
     
    2019     2018      
Product revenues   $ 257,921     $ 264,586      
Cost of sales     182,614       183,344      
Gross margin     75,307       81,242      
Operating expenses:                    
Net research and development expenses     18,897       23,304      
Selling, general and administrative expenses     32,613       36,424      
Acquisition transaction expenses     38            
Restructuring expenses     1,914       865      
    Total operating expenses     53,462       60,593      
Operating income     21,845       20,649      
Interest expense     (1,368 )     (1,180 )    
Foreign currency gain (loss)     203       (4,578 )    
Gain on sale of business     4,970            
Impairment loss     (10,484 )          
Other income     143       1,111      
Earnings before income tax     15,309       16,002      
Income tax expense     6,895       3,036      
Net income   $ 8,414     $ 12,966      
Basic earnings per share   $ 0.25     $ 0.35      
Diluted earnings per share   $ 0.25     $ 0.35      
Weighted average number of shares – basic     33,573       36,766      
Weighted average number of shares – diluted     33,733       36,873      


GENTHERM INCORPORATED
REVENUE BY PRODUCT CATEGORY
(Unaudited, in thousands)
 
    Three Months Ended
March 31,
             
    2019     2018     %
Diff.
   
Climate Control Seat (CCS®)   $ 94,354     $ 88,218       7.0   %  
Seat Heaters     73,920       84,220       (12.2 ) %  
Steering Wheel Heaters     16,970       17,557       (3.3 ) %  
Automotive Cables     23,749       26,865       (11.6 ) %  
Battery Thermal Management (BTM)     10,745       4,161       158.2   %  
Electronics     12,852       15,188       (15.4 ) %  
Other Automotive     9,767       6,212       57.2   %  
Subtotal Automotive   $ 242,357     $ 242,421         %  
Remote Power Generation (GPT)     3,959       4,662       (15.1 ) %  
Industrial Chambers     3,418       10,213       (66.5 ) %  
Gentherm Medical     8,187       7,290       12.3   %  
Subtotal Industrial   $ 15,564     $ 22,165       (29.8 ) %  
Total Company   $ 257,921     $ 264,586       (2.5 ) %  
 

 

 
                           
Total Core Businesses (Automotive and Gentherm Medical)   $ 250,544     $ 249,711       0.3   %  
 


GENTHERM INCORPORATED
RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
(Unaudited, in thousands)
 
    Three Months Ended
March 31,
 
    2019     2018  
Net income   $ 8,414     $ 12,966  
Add Back:                
  Income tax expense     6,895       3,036  
  Interest expense     1,368       1,180  
  Depreciation and amortization     10,980       12,820  
Adjustments:                
Restructuring expenses     1,914       865  
Impairment of assets held for sale     10,484        
Gain on sale of a business     (4,970 )      
Acquisition transaction expense     38        
Unrealized currency (gain)/loss     (994 )     3,642  
CFO transition expenses     1,065        
Adjusted EBITDA   $ 35,194     $ 34,509  

Use of Non-GAAP Financial Measures
In evaluating its business, Gentherm considers and uses Adjusted EBITDA as a supplemental measure of its operating performance. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, transaction expenses, debt retirement expenses, impairment of assets held for sale, restructuring expenses, unrealized currency gain or loss and unrealized revaluation of derivatives. Management believes that Adjusted EBITDA is a meaningful measure of liquidity and the Company's ability to service debt because it provides a measure of cash available for such purposes. Management provides an Adjusted EBITDA measure so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis.

The term Adjusted EBITDA is not defined under GAAP, and is not a measure of operating income, operating performance or liquidity presented in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool, and when assessing the Company's operating performance, investors should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP. Gentherm compensates for these limitations by relying primarily on its GAAP results and using Adjusted EBITDA only supplementally.


GENTHERM INCORPORATED
ACQUISITION TRANSACTION EXPENSES, PURCHASE ACCOUNTING IMPACTS
AND OTHER EFFECTS
(Unaudited and in thousands, except per share data)
 
    Three Months Ended
    March 31, 
   Future Full Year Periods (estimated) 
   
    2019 
        2018          2019          2020          2021          2022    Thereafter
               
Transaction related current expenses              
Acquisition transaction expenses     38       –       38       –       –       –       –  
Non-cash purchase accounting impacts              
Customer relationships amortization     1,828       2,665       7,251       5,991       5,461       5,143       18,574  
Technology amortization     482       998       1,913       1,909       1,901       1,843       4,759  
Inventory value adjustment     39       30       39       –       –       –       –  
Trade name amortization     –       –       –       –       –       –       –  
Other effects              
Restructuring expenses     1,914       865       1,914       –       –       –       –  
Gain on sale of a business     (4,970 )     –       (4,970 )     –       –       –       –  
Impairment loss     10,484       –       10,484       –       –       –       –  
Unrealized currency (gain)/loss     (994 )     3,642       (994 )     –       –       –       –  
CFO Transition       1,065         –         1,065         –         –         –         –  

Total acquisition transaction expenses, purchase accounting impacts and other effects

$


    9,886

 
 
$

    8,200
 
$

    16,740
 
$

    7,900
 
$

    7,362
 
$

    6,986
 
$

    23,333
 
Tax effect of above       212         (2,098 )       (1,465 )       (1,950 )       (1,825 )       (1,735 )       (5,791 )
Net income effect $     10,098   $     6,102   $     15,275   $     5,950   $     5,537   $     5,251   $     17,542  
               
Earnings per share – difference              
Basic $     0.30   $     0.17       –       –       –       –       –  
Diluted $     0.30   $     0.17       –       –       –       –       –  
Adjusted earnings per share              
Basic $     0.55   $     0.52       –       –       –       –       –  
Diluted $     0.55   $     0.52       –       –       –       –       –  
               


GENTHERM INCORPORATED
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
(Unaudited)
 
  March 31,
2019
    December 31,
2018
 
ASSETS              
Current Assets:              
Cash and cash equivalents $ 38,769     $ 39,620  
Restricted cash   2,500        
Accounts receivable, less allowance of $1,068 and $851, respectively   175,044       166,858  
Inventory:              
    Raw materials   66,316       61,679  
    Work in process   4,830       5,939  
    Finished goods   40,979       44,917  
        Inventory, net   112,125       112,535  
Derivative financial instruments   857       92  
Prepaid expenses and other assets   55,577       54,271  
Assets held for sale   17,009       69,699  
    Total current assets   401,881       443,075  
Property and equipment, net   168,371       171,380  
Goodwill   54,721       55,311  
Other intangible assets, net   53,188       56,385  
Operating lease right-of-use assets   14,058        
Deferred financing costs   575       647  
Deferred income tax assets   61,032       64,024  
Other non-current assets   9,220       12,225  
   Total assets $ 763,046     $ 803,047  
LIABILITIES AND SHAREHOLDERS’ EQUITY              
Current Liabilities:              
Accounts payable $ 91,286     $ 93,113  
Accrued liabilities   60,907       65,808  
Current lease liabilities   4,203        
Current maturities of long-term debt   2,949       3,413  
Liabilities held for sale   7,009       13,062  
      Total current liabilities   166,354       175,396  
Pension benefit obligation   6,755       7,211  
Non-current lease liabilities   9,307        
Long-term debt, less current maturities   97,604       136,477  
Deferred income tax liabilities   1,649       1,177  
Other non-current liabilities   2,890       3,087  
    Total liabilities   284,559       323,348  
Shareholders’ equity:              
Common Stock:              
    No par value; 55,000,000 shares authorized, 33,653,179 and 33,856,629 issued and outstanding at March 31, 2019 and December 31, 2018, respectively   134,486       140,300  
Paid-in capital   14,513       14,934  
Accumulated other comprehensive loss   (43,152 )     (39,500 )
Accumulated earnings   372,640       363,965  
     Total shareholders’ equity   478,487       479,699  
     Total liabilities and shareholders’ equity $ 763,046     $ 803,047  


GENTHERM INCORPORATED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
 
  Three Months Ended March 31,  
  2019     2018  
Operating Activities:              
Net income $ 8,414     $ 12,966  
Adjustments to reconcile net income to cash provided by operating activities:              
    Depreciation and amortization   11,052       12,892  
    Deferred income taxes   1,749       (707 )
    Stock compensation   1,968       2,202  
    Defined benefit plan (income) expense   (617 )     298  
    Provision of doubtful accounts   229       41  
    Loss on sale of property and equipment   178       85  
    Operating lease expense   1,333        
    Impairment loss   10,484        
    Gain on sale of business   (4,970 )      
    Changes in operating assets and liabilities:              
          Accounts receivable   (8,293 )     (9,691 )
          Inventory   (229 )     1,903  
          Prepaid expenses and other assets   (5,553 )     (4,881 )
          Accounts payable   (2,079 )     1,290  
          Accrued liabilities   (6,785 )     (10,808 )
Net cash provided by operating activities   6,881       5,590  
Investing Activities:              
Proceeds from the sale of property and equipment   28        
Proceeds from the sale of a business   47,500        
Final payment for acquisition of subsidiary, net of cash acquired         (15 )
Purchases of property and equipment   (5,150 )     (8,378 )
    Net cash provided by (used in) investing activities   42,378       (8,393 )
Financing Activities:              
Borrowing of debt   10,428        
Repayments of debt   (49,627 )     (35,492 )
Cash paid for the cancellation of restricted stock   (376 )     (659 )
Proceeds from the exercise of Common Stock options   214       751  
Repurchase of Common Stock   (8,040 )      
          Net cash used in financing activities   (47,401 )     (35,400 )
          Foreign currency effect   (209 )     5,513  
          Net increase (decrease) in cash, cash equivalents and restricted cash   1,649       (32,690 )
          Cash, cash equivalents and restricted cash at beginning of period   39,620       103,172  
          Cash, cash equivalents and restricted cash at end of period $ 41,269     $ 70,482  
Supplemental disclosure of cash flow information:              
Cash paid for taxes $ 3,466     $ 6,870  
Cash paid for interest $ 1,252     $ 981  
Supplemental disclosure of non-cash transactions:              
Common Stock issued to Board of Directors and employees $ 1,581     $ 1,362  


 

THRM_LOGO.png

Source: Gentherm Inc.